GB201522309D0 - Use - Google Patents

Use

Info

Publication number
GB201522309D0
GB201522309D0 GBGB1522309.2A GB201522309A GB201522309D0 GB 201522309 D0 GB201522309 D0 GB 201522309D0 GB 201522309 A GB201522309 A GB 201522309A GB 201522309 D0 GB201522309 D0 GB 201522309D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1522309.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure ASA filed Critical Photocure ASA
Priority to GBGB1522309.2A priority Critical patent/GB201522309D0/en
Publication of GB201522309D0 publication Critical patent/GB201522309D0/en
Priority to CN202411498667.9A priority patent/CN119345359A/zh
Priority to DK16819894.3T priority patent/DK3389717T3/da
Priority to CA3008551A priority patent/CA3008551C/en
Priority to PL16819894.3T priority patent/PL3389717T3/pl
Priority to KR1020187020006A priority patent/KR102787188B1/ko
Priority to FIEP16819894.3T priority patent/FI3389717T3/fi
Priority to ES16819894T priority patent/ES3015668T3/es
Priority to US16/063,185 priority patent/US10556010B2/en
Priority to CN201680079674.2A priority patent/CN108601836A/zh
Priority to AU2016372573A priority patent/AU2016372573B2/en
Priority to JP2018531667A priority patent/JP6926086B2/ja
Priority to EP16819894.3A priority patent/EP3389717B9/en
Priority to PCT/EP2016/081803 priority patent/WO2017103283A1/en
Priority to RU2018124868A priority patent/RU2783177C2/ru
Priority to BR112018012009-0A priority patent/BR112018012009B1/pt
Priority to US16/748,332 priority patent/US11311620B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/061—Bladder and/or urethra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A61N2005/0629—Sequential activation of light sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1522309.2A 2015-12-17 2015-12-17 Use Ceased GB201522309D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB1522309.2A GB201522309D0 (en) 2015-12-17 2015-12-17 Use
BR112018012009-0A BR112018012009B1 (pt) 2015-12-17 2016-12-19 Uso de hexil 5-ala éster (hal) ou um sal farmaceuticamente aceitável do mesmo
US16/063,185 US10556010B2 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
AU2016372573A AU2016372573B2 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
CA3008551A CA3008551C (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
PL16819894.3T PL3389717T3 (pl) 2015-12-17 2016-12-19 Terapia neoadjuwantowa raka pęcherza moczowego
KR1020187020006A KR102787188B1 (ko) 2015-12-17 2016-12-19 방광암에 대한 신보조 요법
FIEP16819894.3T FI3389717T3 (fi) 2015-12-17 2016-12-19 Neoadjuvanttihoito virtsarakon syöpää varten
ES16819894T ES3015668T3 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
CN202411498667.9A CN119345359A (zh) 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法
CN201680079674.2A CN108601836A (zh) 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法
DK16819894.3T DK3389717T3 (da) 2015-12-17 2016-12-19 Neoadjuvansterapi for blærekræft
JP2018531667A JP6926086B2 (ja) 2015-12-17 2016-12-19 膀胱癌のための術前補助療法
EP16819894.3A EP3389717B9 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
PCT/EP2016/081803 WO2017103283A1 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
RU2018124868A RU2783177C2 (ru) 2015-12-17 2016-12-19 Неоадъювантная терапия для рака мочевого пузыря
US16/748,332 US11311620B2 (en) 2015-12-17 2020-01-21 Neoadjuvant therapy for bladder cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1522309.2A GB201522309D0 (en) 2015-12-17 2015-12-17 Use

Publications (1)

Publication Number Publication Date
GB201522309D0 true GB201522309D0 (en) 2016-02-03

Family

ID=55311159

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1522309.2A Ceased GB201522309D0 (en) 2015-12-17 2015-12-17 Use

Country Status (13)

Country Link
US (2) US10556010B2 (https=)
EP (1) EP3389717B9 (https=)
JP (1) JP6926086B2 (https=)
KR (1) KR102787188B1 (https=)
CN (2) CN108601836A (https=)
AU (1) AU2016372573B2 (https=)
BR (1) BR112018012009B1 (https=)
DK (1) DK3389717T3 (https=)
ES (1) ES3015668T3 (https=)
FI (1) FI3389717T3 (https=)
GB (1) GB201522309D0 (https=)
PL (1) PL3389717T3 (https=)
WO (1) WO2017103283A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
US11266619B2 (en) * 2017-12-01 2022-03-08 Sbi Pharmaceuticals Co., Ltd. Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
KR102441358B1 (ko) 2020-09-14 2022-09-06 주식회사 아파트엔 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템
CN120957714A (zh) 2023-03-07 2025-11-14 光治疗Asa公司 膀胱癌疗法
WO2026052815A1 (en) 2024-09-05 2026-03-12 Photocure Asa Use of hal in a method for predicting bladder cancer immunotherapy response

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE202076T1 (de) 1995-03-10 2001-06-15 Photocure Asa Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
RU2526803C2 (ru) 2009-06-11 2014-08-27 ФотоКьюэр АСА Полутвердые композиции и фармацевтические продукты
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US8927761B2 (en) 2012-06-28 2015-01-06 Photocure Asa Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same
CA2880422C (en) * 2012-08-03 2021-02-09 Photocure Asa Derivatives of 5-aminolevulinic acid
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CN109010850B (zh) * 2018-08-01 2021-10-22 上海师范大学 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用

Also Published As

Publication number Publication date
RU2018124868A3 (https=) 2020-05-13
KR20180094987A (ko) 2018-08-24
US20180369379A1 (en) 2018-12-27
JP2018537514A (ja) 2018-12-20
WO2017103283A1 (en) 2017-06-22
AU2016372573B2 (en) 2022-07-21
EP3389717A1 (en) 2018-10-24
CA3008551A1 (en) 2017-06-22
CN119345359A (zh) 2025-01-24
EP3389717B1 (en) 2025-02-19
FI3389717T3 (fi) 2025-04-08
US20200155683A1 (en) 2020-05-21
BR112018012009A2 (pt) 2018-12-04
CN108601836A (zh) 2018-09-28
US11311620B2 (en) 2022-04-26
DK3389717T3 (da) 2025-03-31
EP3389717B9 (en) 2025-07-23
AU2016372573A1 (en) 2018-07-12
BR112018012009B1 (pt) 2023-12-19
KR102787188B1 (ko) 2025-03-25
ES3015668T3 (en) 2025-05-07
US10556010B2 (en) 2020-02-11
PL3389717T3 (pl) 2025-06-09
JP6926086B2 (ja) 2021-08-25
RU2018124868A (ru) 2020-01-27

Similar Documents

Publication Publication Date Title
DK3256579T5 (en) Cysteinprotease
GB201502152D0 (en) Novel use
DK3250592T3 (en) Anti-transthyretin-antistoffer
GB201509585D0 (en) -
GB201509326D0 (en) Novel use
GB201522309D0 (en) Use
GB201522311D0 (en) Use
DK3133099T3 (en) Polymermodificeret polyoldispersion
GB201521085D0 (en) Use
GB201518466D0 (en) Use
GB201510077D0 (en) Use
GB201518831D0 (en) New use
GB201522443D0 (en) Use
GB201522411D0 (en) Use
GB201515987D0 (en) Use
GB201520225D0 (en) Novel use
GB201513803D0 (en) Novel Use
GB201510628D0 (en) Novel use
GB201518776D0 (en) Pedstay
GB201518560D0 (en) Unrelaxer
GB201518442D0 (en) Drumstring
GB201517684D0 (en) Meccano
GB201517598D0 (en) NoFlat1
GB201515793D0 (en) Dartboards
GB201514804D0 (en) Framed-rucksack-folding-chair

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)